L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
SAN DIEGO, Oct. 13, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 11:30 a.m. PT on Wednesday, October 18, at the BIO Investor Forum Conference (San Francisco – October 17-18). A webcast of the company’s presentation will be available live through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact:
Tony Ramos
(858) 646-1127
Website: www.vical.com
